Sesha Neervannan

Sesha has over 25 years of experience in the global development of novel therapeutics. Prior to joining Tarsus, he was a Senior Vice President of Global Pharmaceutical Development at Allergan (an AbbVie company), where he built strong and nimble early development functions to rapidly enable proofs of concept as well as a robust late-stage development organization for product approval and commercialization of small molecules and biologics. He also established industry-leading expertise in drug delivery technologies in multiple ocular, oral, and dermal product development programs; regulatory filings; and approvals, including novel intraocular, sustained-release injectables (Ozurdex®, Durysta®), a multidose non-preserved drug product in a first-ever container-closure delivery system (Restasis MultiDose®), topical dermal products (Rhofade® Cream, Aczone® Gel 7.5%), and several Rx and OTC topical ophthalmic products.

Prior to joining Allergan in 2007, Sesha was Director, Pharmaceutics R&D at Amgen Inc., where he oversaw CMC functions and assisted in building early development functions, primarily focusing on a discovery-development interface to enable pipeline advancement. Earlier in his career, he was Senior Research Investigator at Bristol-Myers Squibb Pharmaceutical Research Institute. He received his PhD in Pharmaceutical Chemistry from the University of Kansas. Sesha is active in community charity services and has served on the Board of Greater Irvine Chamber of Commerce, as well as on scientific advisory boards of non-profit organizations and start-up companies.